The EuCARE project gathers a comprehensive multidisciplinary team of clinicians, virologists, epidemiologists, statisticians and top experts in artificial intelligence to unveil the impact of SARS-CoV-2 variants on key sectors of public health, as addressed by the call. The specific activities include: 1. The assessment of natural and artificial immunity to the different viral variants in health care workers with the aim of defining the cross-immunization patterns and the risk of vaccine escape, informing vaccination strategies for the general population; 2. The analysis of the clinical course and long-term follow-up of hospitalized COVID-19 patients to derive the role of different viral variants in the outcome of the infection, including post-acute sequelae of SARS-CoV-2 infection; 3. The definition of the best strategies to control the spread of different viral variants in schools, by comparing the outcome of diverse containment and prevention measures in relation to the prevalence and dynamics of the variants. To ensure a suitable representativeness of the different variants, vaccines and preventive measures, EuCARE has secured the appropriate cohorts from diverse geographic areas including European countries, Kenya, Mexico, Russia and Vietnam, and will consolidate or expand interactions with other cohorts. To deal with complex interactions among many variables, including large dimensional parameters, EuCARE harnesses the power of artificial intelligence to define the role of viral variants and inform clinical guidelines and prevention measures. In the longer-term, EuCARE is committed to maintain active cooperation beyond the duration of the project with a dedicated task in the project. The solid IT and ethics infrastructure and the harmonised research procedures will make the cohort and laboratory network rapidly available to tackle newly emerging infectious diseases, thus contributing to pandemic preparedness on a global scale.

CARE brings together distinguished scientists and highly representative networks in the European region, including Russia, in the fight against HIV/TB/HCV. CARE research objectives are based on already established European cohort networks with extensive and longitudinal data and/or sample collections. Together with new data and sample collections and cohorts created during the project, CARE will produce high-level researchoutputs during the two years of the project timeframe. The specific short term objectives are to: ● Discover and validate novel soluble biomarkers of MDR-TB treatment success and of pulmonary TB. ● Explore host genetic mechanisms of susceptibility to extrapulmonary TB. ● Analyse genotype to phenotype correlations in MDR-TB and develop a decision making support tool. ● Define epidemiology and pathways of drug-resistant HIV, including their relationship with HIV subtypes and TB coinfection to support an evidence-based introduction of INSTIs as part of first line antiretroviral therapy. ● Discover and validate host genomic variants influencing susceptibility to contracting AIDS and serious non-AIDS clinical events and adverse reactions to drugs. ● Derive best practice recommendations for DAA prioritisation strategies for HCV treatment. The longer-term objective of CARE is to implement a research infrastructure that allows the expansion of activities beyond the funding frame, permitting the partners to share technology, protocols, structured data collections and knowledge. Finally, CARE activities include realization of recommendations and intervention plans, communication to the stakeholders, dissemination and training activities in order to develop and distribute the highest expertise and competence throughout the European region for the containment of the epidemics.CARE is fully in line with the call topic and addresses all its subtopics. It involves a recognised Russian partner coordinating 5 top level institutions covering the regions of Russia.